FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes
The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Food and Drug Administration (FDA) | Heart | Jardiance